Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orthofix MedicalOFIX -2.00%57 Debt-to-EBITDA is 10.76 as of Jun. 2026, which is 852% above its 10-year median of 1.13. GuruFocus rates OFIX with a GF Score™ of 57/100 and a GF Value™ of $13.93 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Orthofix Medical ranks worse than 93.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Orthofix Medical's Debt-to-EBITDA or its related term are showing as below:
OFIX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.83 Med: 1.13 Max: 17.96
Current: 12.36
During the past 13 years, the highest Debt-to-EBITDA Ratio of Orthofix Medical was 17.96. The lowest was -9.83. And the median was 1.13.
OFIX's Debt-to-EBITDA is ranked worse than 93.89% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs OFIX: 12.36
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Orthofix Medical Debt-to-EBITDA Related Terms
Orthofix Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Orthofix Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OFIX vs VMD, VREX, KIDS: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Orthofix Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthofix Medical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orthofix Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Orthofix Medical (OFIX) has a Debt-to-EBITDA of 10.76 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orthofix Medical. This is 852% above median its historical median of 1.13. According to the industry distribution chart, Orthofix Medical ranks #446 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 93.9%.
Is Orthofix Medical's Debt-to-EBITDA too high?
Orthofix Medical's current Debt-to-EBITDA of 10.76 is 852% above median its 10-year median of 1.13. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Orthofix Medical's value of 10.76 is 560.1% above this industry median. Based on the distribution chart, Orthofix Medical ranks #446 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Orthofix Medical has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's Debt-to-EBITDA compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Orthofix Medical ranks #446 out of 475 companies for Debt-to-EBITDA. This places Orthofix Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Orthofix Medical's value of 10.76 is 560.1% above this benchmark. While the company's 10-year median is 1.13 vs. the industry median of 1.63, Orthofix Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orthofix Medical's current Debt-to-EBITDA of 10.76 is 560.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orthofix Medical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthofix Medical's current Debt-to-EBITDA is 10.76, which is 852% above median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (OFIX) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.93, compared to a current price of $9.81 — trading 29.6% below its estimated fair value. The current Debt-to-EBITDA is 10.76, which is 852% above median its 10-year median of 1.13 and 560.1% above the Medical Devices & Instruments industry median of 1.63. Orthofix Medical's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Orthofix Medical (OFIX), the current Debt-to-EBITDA is 10.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthofix Medical (OFIX) Overvalued in 2026?
Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued.
The current stock price of $9.81 is trading 29.6% below its estimated GF Value™ of $13.93.
GuruFocus considers Orthofix Medical to be Modestly Undervalued.
Key valuation signals for OFIX:
Debt-to-EBITDA: 10.76 (852% above median its 10-year median of 1.13)
GF Value™: $13.93 vs. price of $9.81 (29.6% below fair value)
Industry Position: 560.1% above the Medical Devices & Instruments median (#446 of 475)
No single metric tells the full story. See the OFIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
57GF Score
Get the complete analysis for OFIX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OFIX has been successfully added to your 
